The medical technology space has grown by leaps and bounds in recent times and many companies have come into focus among investors during that time. One of the medical technology companies to have come into focus this week is that of Senseonics Holdings Inc (NYSEAMERICAN:SENS), which announced its financial results for the second fiscal quarter this past Monday.
Major News
The company’s performance seems to have been welcomed by the market and the stock rallied by as much as 5% following the earnings announcement. Due to the gains made by the stock, it could actually be a good idea for investors if they consider having a closer look at Senseonics Holdings and its business.
$RELT – Exclusive interview with Reliant Holdings Inc. a Swiming pool building company
The most important starting point for investors could be the second-quarter earnings report released by Senseonics earlier this week. The company, which is involved in the manufacturing and commercialization of continuous glucose monitoring systems, managed to reduce its net losses considerably year on year. Senseonics posted a net loss of $7.5 million in the quarter but that also reflected a reduction of as much as $23.6 million from the prior-year period.
In March 2020, the company had executed a range of actions to reduce costs and also put plans in place to streamline its operations considerably. However, that is not all. The company also mentioned that it expects to submit the 180 Day Eversence product to the United States Food and Drug Administration.
$FHBC – The chairman of Fernhill Beverage lets us know why they entered a high-potential market
The revenues generated by the company were vastly reduced since commercial operations in the United States had to be suspended. Net revenues for the quarter came in at $261000, which was significantly lower than the $4.6 million that the company had generated in the second quarter last year.
However, at the same time, it should be pointed out that the company’s gross profit for the quarter grew to $3.4 million. In the year-ago period, Senseonics had managed to generate a gross profit of only $1.1 million. At the end of the second quarter, the company reported a cash balance, including equivalents and restricted cash, of $21.6 million.
On the other hand, the outstanding debts stood at $106.4 million. The management also announced that it believes that the annualized cash burn is going to be short of $60 million. Senseonics added that if it can be managed to get 100% of the total financial commitments then it would not be a problem to fund operations until the end of 2021.
On Tuesday, the PHC Holdings Corporation and a constituent of the PHC group Ascensia Diabetes Care announced that they are going into a strategic partnership with Senseonics Holdings. By way of this partnership, there is an agreement regarding a worldwide distribution and commercialization agreement. Additionally, there is also a concurrent financial agreement.
Neither PSN nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision.